Molbio Diagnostics IPO: ₹939.70 Cr Debut Aug 2026

Molbio Diagnostics is set to launch its Initial Public Offering (IPO), aiming to raise approximately ₹939.70 crores. The subscription window runs from August 10 to August 12, 2026.

Key IPO Details

• Total IPO Size: ₹939.70 crores
• Fresh Issue Component: ₹200 crores
• Offer for Sale (OFS): Up to 91,66,000 equity shares
• Price Band: ₹768 to ₹807 per equity share
• Face Value: ₹1 per share
• Retail Minimum Lot Size: 18 shares (₹14,526)

Investor allocation is structured with 50% for Qualified Institutional Buyers (QIB), 15% for Non-Institutional Investors (NII), and 35% for Retail Investors.

IPO Timeline

• Allotment Finalization: August 13, 2026
• Refund Processing: August 14, 2026
• Shares Credited to Demat: August 14, 2026
• BSE and NSE Listing: August 17, 2026

Molbio Diagnostics specializes in rapid, accurate point-of-care (POC) diagnostic solutions. Their flagship product is the portable Truenat PCR testing platform, developed through its subsidiary Bigtec Labs.

Financial Performance (FY2025-2026)

• Revenue 2025: ₹1027.94 crores
• Revenue 2026: ₹1455.17 crores
• Profits 2025: ₹138.58 crores
• Profits 2026: ₹164.14 crores

Based on these financials, the IPO is considered suitable for long-term investment. Promoters include Chandrasekhar Bhaskaran Nair and Sriram Natarajan, among others, with a post-IPO holding of 37.69%.

IPO Proceeds Utilization

The proceeds from the IPO are earmarked for several key initiatives. A total of ₹118.08 crores will fund capital expenditure for a new R&D facility, Center of Excellence, and connected office space.

• Plant, Machinery, Equipment for Goa and Visakhapatnam: ₹79.04 crores
• General Corporate Purposes